Targeting mTOR Shows Promise in Cutaneous Sarcoidosis
Vienna researchers reported that 7 of 10 patients treated with systemic sirolimus had noted improvements in skin lesions, which continued for up to 2 years of follow-up.
Medscape Medical News
source https://www.medscape.com/viewarticle/targeting-mtor-shows-promise-cutaneous-sarcoidosis-2024a100024b?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/targeting-mtor-shows-promise-cutaneous-sarcoidosis-2024a100024b?src=rss
Comments
Post a Comment